Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Lyrica | Pregabalin | Pain, Neuropathic | Do not list | Complete | ||
Sativex | Delta-9-tetrahydrocannabinol/cannabidiol | Pain, Neuropathic (adjunctive) in MS. | Do not list | Complete | ||
Cymbalta | Duloxetine hydrochloride | Pain, Neuropathic, Diabetic | List with clinical criteria and/or conditions | Complete | ||
Visanne | Dienogest | Pain, pelvic pain associated with endometriosis | List with clinical criteria and/or conditions | Complete | ||
Nucynta | tapentadol hydrochloride | pain, severe | Do not reimburse | Complete | ||
Ibrance (with Faslodex) | Palbociclib (with Fulvestrant) | Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Afinitor | Everolimus | Pancreatic Neuroendocrine Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
Sutent | Sunitinib malate | Pancreatic Neuroendocrine Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
Movapo | apomorphine hydrochloride | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Duodopa | Levodopa / carbidopa (Drug Plan Submission) | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete |